Vitamin D3 dose: why 2,000 IU, not 5,000
A question that comes up constantly in supplements discussion — on Reddit, in health podcasts, on the packaging of American vitamin brands — is whether 2,000 IU of vitamin D3 per day is actually sufficient or whether you should be taking 5,000. The short answer: 2,000 IU sits squarely within the Endocrine Society's clinical maintenance recommendation and well under the European Food Safety Authority's tolerable upper limit. The 5,000 IU figure is not a research-derived recommendation for healthy, non-deficient adults — it originates primarily from American wellness culture, not clinical guideline bodies. This article explains exactly where each number comes from and why Krevie's The Foundation uses 2,000 IU of vitamin D3 per serving.
What vitamin D3 is and what it does in the body
Vitamin D is a fat-soluble prohormone, meaning the form you ingest or synthesise in skin is not the active form. Cholecalciferol (vitamin D3) — whether produced in skin following UVB exposure or taken as a supplement — is converted first in the liver to 25-hydroxyvitamin D [25(OH)D], the main circulating form used to assess status in blood tests, and then in the kidneys to 1,25-dihydroxyvitamin D [calcitriol], the biologically active form. Calcitriol acts via the vitamin D receptor (VDR), which is expressed in virtually every cell in the body — skeletal muscle, immune tissue, cardiac tissue, brain, gut epithelium, and parathyroid glands, among many others. This near-universal receptor expression explains why vitamin D status influences outcomes well beyond calcium regulation and bone metabolism.
Vitamin D3 (cholecalciferol) and vitamin D2 (ergocalciferol) are not equivalent at equivalent doses: D3 more effectively raises and sustains circulating 25(OH)D levels. The Foundation uses vegan cholecalciferol — D3 derived from lichen rather than lanolin — specifically to maintain the D3 form without the use of animal-derived raw materials.
The UK problem: latitude and seasonal synthesis
The United Kingdom sits between approximately 50° and 60° north latitude. At these latitudes, the angle at which sunlight strikes the atmosphere during autumn and winter is too oblique for UVB photons (wavelength 290–315 nm) to reach the Earth's surface in quantities sufficient to drive vitamin D3 synthesis in the skin. This is not a marginal effect: from approximately October through to March, cutaneous vitamin D3 synthesis in the UK is effectively zero regardless of how much time is spent outdoors.
During this six-month window, dietary and supplemental intake are the sole sources of vitamin D. The average dietary intake of vitamin D from food in the UK is approximately 3–4 mcg (120–160 IU) per day. The NHS-recommended supplemental intake of 10 mcg (400 IU) per day during autumn and winter is designed to prevent deficiency in the general population — it is a public health floor, not a dose calculated to maintain optimal 25(OH)D concentrations. As reviewed by Holick in the New England Journal of Medicine (PMID 17634462), the VDR's ubiquitous tissue expression and the widespread nature of latitude-related deficiency underscore the clinical importance of adequate supplementation in northern populations.
What the NHS, EFSA, and the Endocrine Society actually say
These three bodies have meaningfully different remits, and conflating their recommendations creates most of the confusion around vitamin D dosing.
| Body | Recommendation | What it represents |
|---|---|---|
| NHS | 10 mcg (400 IU) daily during autumn/winter; year-round for at-risk groups | Public health minimum to prevent deficiency across a general population. Not a target for optimal 25(OH)D; not a clinical maintenance dose. |
| EFSA (European Food Safety Authority) | Tolerable upper intake level: 100 mcg (4,000 IU) per day for adults | A safety ceiling, not a recommended dose. Doses at or below this level are considered safe for long-term daily use in healthy adults without medical supervision. |
| Endocrine Society (Holick et al. 2011) | 1,500–2,000 IU/day as maintenance to sustain 25(OH)D above 30 ng/mL in adults aged 19–70 | A clinical recommendation for achieving and sustaining sufficiency in adults. Based on dose-response modelling in the research literature. |
The NHS figure of 400 IU is not wrong — it reflects what is needed to avoid frank vitamin D deficiency across a population that includes all skin types, activity levels, dietary patterns, and body compositions. But it was not designed to be the upper bound of what people should take. The EFSA figure of 4,000 IU is a safety limit — not a target dose, and not evidence that 4,000 IU is better than 2,000 IU for a non-deficient adult. The Endocrine Society's 1,500–2,000 IU represents a considered clinical position based on the dose-response data: the amount of supplemental D3 required to consistently raise circulating 25(OH)D to concentrations associated with sufficiency.
Where 5,000 IU came from
The 5,000 IU figure that circulates heavily in online wellness communities does not originate from a clinical guideline body or a systematic review of dose-response evidence in the general adult population. It became prominent via American supplement culture — functional medicine practitioners, longevity influencers, and a category of supplement brands that positioned higher doses as more proactive or optimal without published clinical consensus to support that position for non-deficient adults.
There are specific clinical contexts in which higher doses are used: severe deficiency correction typically uses 6,000 IU/day or 50,000 IU/week for 8 weeks under medical supervision, as per Endocrine Society treatment guidelines. Conditions that impair vitamin D absorption or metabolism — including obesity, inflammatory bowel disease, and gastric bypass surgery — may require higher maintenance doses. These are medically supervised contexts. The implication that a healthy, non-deficient adult should routinely supplement at 5,000 IU/day as a maintenance dose is not supported by guideline bodies or by the dose-response research.
5,000 IU is 125% of the EFSA tolerable upper limit for adults. It falls within the range used medically to correct vitamin D deficiency, not to maintain sufficiency in adults who are not deficient. NHS, EFSA, and Endocrine Society guidance collectively places the appropriate daily maintenance range at 400–2,000 IU depending on context and goals. 5,000 IU as a routine supplement dose is not endorsed by any major European or UK guideline body.
The research
The Endocrine Society's comprehensive clinical practice guideline on vitamin D deficiency, authored by Michael Holick and a panel of seven specialists. Based on a systematic review of the dose-response evidence, the guideline recommends that adults aged 19–50 require at least 1,500–2,000 IU/day of supplemental vitamin D3 to raise and sustain circulating 25(OH)D consistently above 30 ng/mL — the threshold considered sufficient for the full range of non-skeletal health benefits associated with adequate vitamin D status.
The guideline further notes that the standard dietary intake of 600 IU/day (the RDA at the time) is adequate to meet bone health targets in most adults but is unlikely to be sufficient to achieve consistent 25(OH)D levels above 30 ng/mL for all individuals. 2,000 IU represents the upper end of the maintenance range recommended by this guideline for healthy adults — not a high dose.
A randomised controlled dose-response trial in 163 postmenopausal women (mean baseline 25(OH)D: 39 nmol/L). Participants received either placebo or one of seven vitamin D3 doses: 400, 800, 1,600, 2,400, 3,200, 4,000, or 4,800 IU daily for 12 months.
Key dose-response finding: The 25(OH)D response was curvilinear — gains per additional IU were greatest at lower doses and progressively diminished at higher doses. The dose-response curve tended to plateau at approximately 112 nmol/L in participants receiving more than 3,200 IU/day. Importantly, 800 IU/day raised 25(OH)D above 50 nmol/L (the basic UK sufficiency threshold) in 97.5% of participants. The increment between 800 IU and 2,000 IU was meaningful; the increment between 2,000 IU and 5,000 IU was marginal in non-deficient participants.
This trial is significant for Krevie's formulation because it was conducted specifically in postmenopausal women — the same population using The Foundation — over a full year of supplementation. The data confirm that 2,000 IU delivers robust 25(OH)D elevation without approaching the dose range where diminishing returns become sharp.
A meta-analysis of 8 randomised controlled trials (971 subjects) examining the effect of combined vitamin K and vitamin D supplementation on bone quality markers. The pooled effect size for total bone mineral density (BMD) was 0.316 (95% CI 0.031–0.601), a statistically significant positive effect. The combined regimen also significantly decreased undercarboxylated osteocalcin, with an effect size of −0.945 (95% CI −1.113 to −0.778).
Subgroup analysis found that the effect was strongest when vitamin K2 (rather than K1) was used. The authors concluded that a more favourable effect is expected when K2 is the K form in the combination — supporting the biological rationale for pairing D3 with K2 specifically, as opposed to K1 or a mixed-K supplement.
The D3-K2 pairing: why it matters
Vitamin D3 and vitamin K2 are frequently combined in supplements because they operate on intersecting pathways in calcium metabolism. Understanding why requires a brief look at osteocalcin biology.
Vitamin D3 increases both intestinal absorption of dietary calcium and renal reabsorption of calcium, raising the amount of calcium available in the bloodstream. This is the mechanism underlying D3's well-established role in bone mineralisation — more calcium absorbed means more calcium available for incorporation into bone matrix. However, calcium's destination in the body is not automatically the skeleton.
Osteocalcin is a bone matrix protein synthesised by osteoblasts (bone-forming cells). It must be carboxylated — a post-translational modification that adds a negatively charged group to specific glutamic acid residues — before it can bind calcium ions effectively and anchor them into bone mineral. The carboxylation of osteocalcin is dependent on vitamin K as a cofactor for the enzyme gamma-glutamyl carboxylase. Without adequate vitamin K, a substantial proportion of osteocalcin circulates in an undercarboxylated (inactive) form, which is less effective at directing calcium to bone.
The clinical implication: supplementing with D3 alone increases calcium availability, but if K2 status is insufficient, the carboxylation step is rate-limiting and not all of that calcium reaches bone efficiently. The Kuang 2020 meta-analysis (PMID 32219282) quantified this — K+D combined significantly improved BMD and significantly decreased undercarboxylated osteocalcin compared to either alone, with K2 producing a more favourable effect than K1.
MK-7 (menaquinone-7) is the form of K2 used in The Foundation at 100 mcg per serving. MK-7 has a substantially longer biological half-life than other menaquinone forms — approximately three days versus a few hours for MK-4 — making it the most practical K2 form for daily supplementation at the doses shown to be effective in clinical research.
Why Krevie uses 2,000 IU
The Foundation's 2,000 IU dose of vitamin D3 per daily serving was chosen for three specific reasons:
- It matches the Endocrine Society maintenance recommendation. Holick et al. 2011 (PMID 21646368) recommends 1,500–2,000 IU/day for adults to consistently sustain 25(OH)D above 30 ng/mL. 2,000 IU is the upper end of this clinical maintenance range.
- It sits well within the EFSA safety ceiling. At 50 mcg (2,000 IU), The Foundation's dose is exactly 50% of EFSA's 4,000 IU tolerable upper intake level for adults. There is substantial headroom below the safety limit, and no evidence that doubling the dose from 2,000 to 4,000 IU produces proportional benefit in non-deficient adults.
- It reflects the dose-response data. The Gallagher 2012 trial in postmenopausal women demonstrated that the dose-response curve becomes progressively less steep above approximately 1,600–2,000 IU in participants who are not starting severely deficient. The marginal gain from increasing beyond 2,000 IU in this population is small; the safety headroom below the EFSA limit is substantial. 2,000 IU represents a well-evidenced point on the curve.
The Foundation delivers 2,000 IU of vegan cholecalciferol (D3 from lichen) alongside 100 mcg of MK-7 vitamin K2, providing both the dose and the molecular partner that the combined K+D research supports.
How it's used in Krevie
Product: The Foundation
Vitamin D3 dose: 2,000 IU (50 mcg) vegan cholecalciferol per daily serving (2 capsules)
Vitamin K2 dose: 100 mcg MK-7 (menaquinone-7) per daily serving
The 2,000 IU dose places The Foundation at the upper end of the Endocrine Society's 1,500–2,000 IU maintenance recommendation for adults and at 50% of the EFSA tolerable upper limit. It is paired with 100 mcg MK-7 K2 to support osteocalcin carboxylation — the step that directs calcium absorption towards bone rather than leaving it unanchored in the bloodstream. Two capsules daily with food.
Frequently asked questions
Is 2,000 IU of vitamin D3 enough per day?
For most adults who are not severely vitamin D deficient, 2,000 IU per day is sufficient to achieve and maintain circulating 25(OH)D levels above the sufficiency threshold of 30 ng/mL. The Endocrine Society (Holick et al. 2011) recommends 1,500–2,000 IU/day for adults as a maintenance dose. The EFSA tolerable upper limit for adults is 4,000 IU/day, making 2,000 IU exactly 50% of the safety ceiling. If you are diagnosed with vitamin D deficiency, your GP may recommend a short-term higher-dose correction course before moving to a maintenance dose.
Why do some people recommend 5,000 IU of vitamin D?
The 5,000 IU recommendation circulates primarily in American wellness and functional medicine communities rather than from UK or European guideline bodies. 5,000 IU is a dose used clinically to correct vitamin D deficiency under medical supervision — not a maintenance dose for healthy, non-deficient adults. It also exceeds EFSA's 4,000 IU tolerable upper limit for long-term daily use by 25%. For the purpose of maintaining adequate vitamin D status in adults, clinical guidelines recommend 1,500–2,000 IU. Higher doses should be taken only under medical guidance.
What is the NHS recommended vitamin D dose?
The NHS recommends 10 micrograms (400 IU) of vitamin D daily during autumn and winter for most adults, and year-round for those at higher risk of deficiency (including people who are housebound, cover most of their skin outdoors, or have darker skin). The NHS also states that adults should not exceed 100 micrograms (4,000 IU) per day — the same upper limit set by EFSA. The 400 IU figure is a public health minimum to prevent deficiency across the population, not a target for optimal 25(OH)D concentrations; the Endocrine Society places the maintenance target range at 1,500–2,000 IU.
Why is vitamin K2 included with D3 in The Foundation?
Vitamin D3 increases the amount of calcium absorbed from food and supplements. Vitamin K2 is required as a cofactor for the carboxylation of osteocalcin — the bone matrix protein that binds and directs calcium into bone mineral. Without adequate K2, osteocalcin circulates in an undercarboxylated form that is less effective at anchoring calcium to bone. A meta-analysis by Kuang et al. 2020 (PMID 32219282, 8 RCTs, 971 subjects) found that combined K+D supplementation significantly increased total BMD (effect size 0.316) and significantly decreased undercarboxylated osteocalcin, with the largest effects seen when K2 specifically was used. The Foundation uses MK-7 (menaquinone-7) at 100 mcg — the K2 form with the longest biological half-life.
Can I get enough vitamin D from sunlight in the UK?
From approximately October through to March, the answer is no. At UK latitudes (50–60° north), the solar angle in autumn and winter means that UVB photons — the specific wavelengths (290–315 nm) that drive cutaneous vitamin D3 synthesis — do not reach the surface in sufficient quantities to produce vitamin D in skin. Supplementation during this period is the only reliable way to maintain vitamin D status from dietary or supplemental sources in the UK. Between April and September, 10–15 minutes of midday sun on forearms and face is generally sufficient for most adults with lighter skin; people with darker skin, those who cover most of their skin outdoors, or those who spend limited time outdoors may not synthesise adequate amounts even in summer.
Further reading
Food supplements are not a substitute for a varied, balanced diet and a healthy lifestyle. Do not exceed the recommended daily dose. Always speak to your GP if you are taking medication or have a medical condition.
Leave a comment
This site is protected by hCaptcha and the hCaptcha Privacy Policy and Terms of Service apply.